Clinical trials: Postmenopausal Women With Osteoporosis
Osteoporosis
Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)
This study will assess the effect of 26 weeks of once-weekly treatment with MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) on serum levels of 25-hydroxyvitamin D [25(OH)D].
- Trial name
- NCT01437111
- Testing
- MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet
- Volunteers
- 200 people
- Sponsor
- Organon and Co
Osteoporosis, Post-Menopausal
Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
To see if using teriparatide for 12 months will increase Bone Mineral Density at the lumbar spine in postmenopausal women with osteoporosis
- Trial name
- NCT00532207
- Testing
- teriparatide
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
An Investigation Into the Short Term Effect of APOMINE in Patients With Osteoporosis or Low Bone Mass
Osteoporosis affects millions of postmenopausal women in the USA. The current approved treatments are all drugs that prevent bone loss and possibly result in small gains in bone mass.
- Trial name
- NCT00078026
- Testing
- Apomine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Osteoporosis, Osteopenia
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
The purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects…
- Trial name
- NCT00330460
- Testing
- Alendronate, Denosumab
- Volunteers
- 1,189 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.
- Trial name
- NCT00293813
- Testing
- Alendronate, Denosumab
- Volunteers
- 247 people
- Sponsor
- Amgen
Osteoporosis
Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis
The purpose of this study is to assess the clinical efficacy, safety, and tolerability of ViaDerm-shPTH [1-34] transdermal delivery in comparison to subcutaneous injection of rhPTH[1-34] following 3-month treatment in…
- Trial name
- NCT00535860
- Testing
- Teriparatide
- Where
- 10 sites in Czechia, Hungary and 1 more
- Volunteers
- 104 people
- Sponsor
- TransPharma Medical
Postmenopausal Women Osteoporosis
Post-menopausal Women Osteoporosis(Phase III)
The purpose of this study is to evaluate the efficacy and the safety of Risedronate, cholecalciferol combination tablet in patients with Osteoporosis
- Trial name
- NCT01806792
- Testing
- risedronate combine, Risedronate
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Postmenopausal Osteoporosis
A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months.
- Trial name
- NCT00493532
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 14 sites in Taiwan
- Sponsor
- Hoffmann-La Roche
Postmenopausal Osteoporosis
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects
This study is designed to investigate the safety and tolerability of PTH134 in healthy subjects and to assess the exposure from PTH134.
- Trial name
- NCT00676312
- Testing
- PTH134
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Novartis
Postmenopausal Osteoporosis
G56W1 in Women With Postmenopausal Osteoporosis
This study will assess the pharmacokinetics and safety and explore therapeutic effects with once-weekly recombinant human parathyroid hormone for injection ( 1-34 ) ( G56W1 ) in women with post-menopausal osteoporosis .The…
- Trial name
- NCT03720886
- Testing
- rhPTH（1-34） 28.2μg, rhPTH（1-34） 56.5μg, teriparatide acetate(Teribone™)
- Where
- 9 sites in China
- Volunteers
- 148 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Osteoporosis, Osteopenia
Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women
The purpose of this study is to determine whether the intake of a daily dosage of standardized olive extract provides any protection against bone loss.
- Trial name
- NCT00789425
- Testing
- Standardized Extract of Olive Polyphenols
- Where
- Poland
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- BioActor
Osteoporosis
Bone Effects of Teriparatide Following Alendronate
The purpose of this study is to assess the effect of 24 months of treatment with once daily teriparatide injection (recombinant human PTH [1-34]) 20 micrograms on bone histomorphometry and architecture.
- Trial name
- NCT00191893
- Testing
- teriparatide
- Where
- 2 sites in Austria, Czechia
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Post Menopausal Osteoporosis
Evaluation of Adherence With Bisphosphonates and Calcium and Vitamin D Supplements in Women With Postmenopausal Osteoporosis
This study aims to evaluate the adherence of patients to combined treatment with bisphosphonates and calcium and vitamin D supplements, which is one of the usual treatments for postmenopausal osteoporosis.
- Trial name
- OSTEOAD (NCT07105163)
- Where
- 20 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Procare Health Iberia S.L.
Osteoporosis, Age-Related
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.
- Trial name
- NCT02732210
- Where
- 89 sites in United States, Canada
- Volunteers
- 935 people
- Sponsor
- Amgen
Post Menopausal Osteoporosis
ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study.
- Trial name
- NCT00545090
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 17 sites in Hong Kong, Indonesia and 3 more
- Volunteers
- 561 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)
The primary objective of this study is to assess the impact of physician's reinforcement using bone marker data on the subject's compliance (at least 50% drug taken) and persistence on treatment after one year in postmenopausal…
- Trial name
- NCT00268632
- Testing
- risedronate
- Sponsor
- Sanofi
Low Bone Mass, Low Bone Mineral Density
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
To characterize the effects of discontinuation of denosumab therapy on variables of bone histology in postmenopausal women with low bone mass or osteoporosis.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Osteoporosis, Postmenopausal Osteoporosis
- Trial name
- NCT00887965
- Testing
- Previous denosumab
- Volunteers
- 15 people
- Sponsor
- Amgen
Osteoporosis
TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density
This is a placebo-controlled, single-ascending dose, multicenter Phase I clinical study to evaluate the safety, tolerability, PK and PD characteristics of a single intravenous infusion of TST002 in subjects with reduced bone…
- Trial name
- NCT05391776
- Testing
- TST002 Injection
- Where
- 5 sites in China
- Volunteers
- 32 people
- Sponsor
- HJB (Hangzhou) Co., Ltd.
Osteoporosis
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)
The purpose of this study is to assess to what extent sequential treatment with odanacatib results in incremental gains in bone mineral density (BMD) over time in female participants who have received at least 3 years of…
- Trial name
- NCT01803607
- Testing
- odanacatib
- Volunteers
- 135 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
This is an 18-month, double-blind, placebo-controlled, Phase III trial with a 12-month interim analysis of the effect of ALX1-11, recombinant human parathyroid hormone (1-84) (rhPTH [1-84]), on fracture incidence in women with…
- Trial name
- NCT00172081
- Testing
- ALX1-11
- Where
- 174 sites in United States, Argentina and 7 more
- Volunteers
- 2,532 people
- Sponsor
- Shire